Parkman Healthcare Partners LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Parkman Healthcare Partners LLC increased its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 6.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 276,890 shares of the company's stock after acquiring an additional 16,664 shares during the period. Parkman Healthcare Partners LLC owned approximately 1.06% of Eton Pharmaceuticals worth $3,688,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ETON. XTX Topco Ltd boosted its holdings in Eton Pharmaceuticals by 29.6% in the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock worth $195,000 after buying an additional 3,351 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $86,000. Jefferies Financial Group Inc. purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth $133,000. Bank of America Corp DE grew its stake in shares of Eton Pharmaceuticals by 5,422.4% during the fourth quarter. Bank of America Corp DE now owns 11,100 shares of the company's stock worth $148,000 after purchasing an additional 10,899 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth $147,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ETON shares. Craig Hallum raised their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, March 19th. B. Riley reaffirmed a "buy" rating and set a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, HC Wainwright reissued a "buy" rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $17.07 on Wednesday. The firm has a 50-day simple moving average of $14.55 and a 200 day simple moving average of $13.71. Eton Pharmaceuticals, Inc. has a twelve month low of $3.18 and a twelve month high of $18.41. The stock has a market cap of $457.78 million, a PE ratio of -77.59 and a beta of 1.22.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.02. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. Research analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Want to see what other hedge funds are holding ETON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.